Minerva Neurosciences, INC

Minerva Neurosciences' stockholders approved amendments to the company's charter and bylaws at the 2026 Annual Meeting, impacting officer liability, forum selection, and meeting procedures.

Minerva Neurosciences has entered into a Sales Agreement for an at-the-market offering program, potentially raising up to $75 million, while also updating its Phase 3 schizophrenia trial timeline.

Minerva Neurosciences reported Q1 2026 financial results, highlighting the initiation of its Phase 3 trial for roluperidone for negative schizophrenia symptoms and a significant increase in R&D and G&A expenses.

Minerva Neurosciences announced its 2026 annual meeting of stockholders will be held on June 3, 2026, with specific deadlines for stockholder proposals and nominations.

Minerva Neurosciences announced further details regarding its planned confirmatory Phase 3 trial for roluperidone in schizophrenia, with initiation expected in Q2 2026.

Minerva Neurosciences' stockholders approved a significant increase in authorized common stock and equity incentive plan shares, alongside director elections and auditor ratification at its 2025 Annual Meeting.

Minerva Neurosciences reports significant increase in R&D and G&A expenses for Q1 2026, driven by the C19 trial initiation and a settlement agreement, while cash reserves remain a key focus for ongoing operations.

Minerva Neurosciences reported a net loss for Q3 2025 and secured up to $200 million in a private placement to fund a new confirmatory Phase 3 trial for roluperidone after an FDA Complete Response Letter.

Minerva Neurosciences reports reduced losses but faces a new confirmatory clinical trial requirement for its lead drug roluperidone and is exploring strategic alternatives due to its cash position.

Minerva Neurosciences announces its Q1 2025 financial results, highlighting a decrease in research and development expenses and providing an update on the regulatory status of roluperidone following a Complete Response Letter from the FDA.

Minerva Neurosciences reported a net income of $5.7 million for the nine months ended September 30, 2024, primarily due to a significant gain from a royalty liability adjustment, despite ongoing operating losses.

Minerva Neurosciences reported a net loss of $16.8 million for the first half of 2024 and is navigating challenges with its lead drug candidate's regulatory approval.

Minerva Neurosciences files an amendment to its annual report to include missing Inline eXtensible Business Reporting Language (XBRL) data tagging.

Minerva Neurosciences files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and executive compensation.

Minerva Neurosciences reports a net income of $1.4 million for 2024 but faces challenges as the FDA issues a Complete Response Letter for its roluperidone NDA, requiring additional studies.

Minerva Neurosciences has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Minerva Neurosciences has filed an amendment to its annual report to correct a typographical error in the date of the independent auditor's consent.

Minerva Neurosciences has filed its annual 10-K report, detailing its financial status and providing updates on its key drug development programs, particularly roluperidone.

Inderjit Kaul, a Director of Minerva Neurosciences, Inc., received 12,147 shares of common stock on August 3, 2026.

Frederick W. Ahlholm, SVP and CFO of Minerva Neurosciences, was granted 680,000 employee stock options.

CEO Remy Luthringer was granted 1,690,700 employee stock options in Minerva Neurosciences, Inc. as part of a long-term incentive plan.

Director Fouzia Laghrissi-Thode was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of a standard equity incentive.

Minerva Neurosciences director David Kupfer was granted 50,000 stock options as part of his non-employee director compensation.

Director Inderjit Kaul was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of a standard equity compensation package.

Minerva Neurosciences announces its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to be held virtually, with key proposals including director elections and charter amendments.

Minerva Neurosciences will hold its 2025 Annual Meeting to vote on increasing authorized shares, approving Series A Preferred Stock conversion, and amending its equity incentive plan, crucial for future funding and talent retention.

Minerva Neurosciences, Inc. announces its 2024 Annual Meeting of Stockholders to be held on December 5, 2024, with voting open until December 4, 2024.

Minerva Neurosciences will hold its annual stockholders meeting virtually on December 5, 2024, to vote on director elections, executive compensation, and auditor ratification.

Boehringer Ingelheim International GmbH has filed an exit amendment to its Schedule 13D, reporting a beneficial ownership of 3.4% in Minerva Neurosciences, Inc. due to an increase in outstanding shares.

Federated Hermes and affiliated entities have increased their beneficial ownership in Minerva Neurosciences, Inc. to 19.32% and committed to support a significant private placement.

Federated Hermes, Inc. and associated entities have filed a Schedule 13G, reporting beneficial ownership of 17.17% of Minerva Neurosciences, Inc. common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 9.9% of Minerva Neurosciences, Inc. common stock, holding 4,307,759 shares.

Balyasny Asset Management and its affiliates have reported a 9.99% beneficial ownership stake in Minerva Neurosciences, Inc. common stock.

Adage Capital Management, L.P. and its principals have reported a 6.35% beneficial ownership stake in Minerva Neurosciences, Inc. as of December 31, 2025.

Farallon Capital Management and its affiliates updated their beneficial ownership in Minerva Neurosciences, Inc., reflecting personnel changes and a 9.99% aggregate stake.

Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. have disclosed passive beneficial ownership stakes of 9.99% each in Minerva Neurosciences, Inc. common stock.